TY - JOUR
T1 - Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada
AU - Cressman, Sonya
AU - Lam, Stephen
AU - Tammemagi, Martin C.
AU - Evans, William K.
AU - Leighl, Natasha B.
AU - Regier, Dean A.
AU - Bolbocean, Corneliu
AU - Shepherd, Frances A.
AU - Tsao, Ming Sound
AU - Manos, Daria
AU - Liu, Geoffrey
AU - Atkar-Khattra, Sukhinder
AU - Cromwell, Ian
AU - Johnston, Michael R.
AU - Mayo, John R.
AU - McWilliams, Annette
AU - Couture, Christian
AU - English, John C.
AU - Goffin, John
AU - Hwang, David M.
AU - Puksa, Serge
AU - Roberts, Heidi
AU - Tremblay, Alain
AU - MacEachern, Paul
AU - Burrowes, Paul
AU - Bhatia, Rick
AU - Finley, Richard J.
AU - Goss, Glenwood D.
AU - Nicholas, Garth
AU - Seely, Jean M.
AU - Sekhon, Harmanjatinder S.
AU - Frcsc, John Yee
AU - Amjadi, Kayvan
AU - Cutz, Jean Claude
AU - Ionescu, Diana N.
AU - Yasufuku, Kazuhiro
AU - Martel, Simon
AU - Soghrati, Kamyar
AU - Sin, Don D.
AU - Tan, Wan C.
AU - Urbanski, Stefan
AU - Xu, Zhaolin
AU - Peacock, Stuart J.
N1 - Funding Information:
This project was funded in part by the Terry Fox Research Institute, the Canadian Partnership Against Cancer, with cofunding by the Princess Margaret Cancer Foundation Lusi Wong Fund (Toronto site). The Canadian Centre for Applied Research in Cancer Control (ARCC) is funded by the Canadian Cancer Society Research Institute.
Publisher Copyright:
Copyright © 2014 by the International Association for the Study of Lung Cancer.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Background: It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs. Methods: Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study. Results: The average per-person cost for screening individuals with LDCT was $453 (95% confidence interval [CI], $400-$505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was $33,344 (95% CI, $31,553-$34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% CI, $43,254-$52,200; p = 0.061). Conclusion: In the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure.
AB - Background: It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs. Methods: Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study. Results: The average per-person cost for screening individuals with LDCT was $453 (95% confidence interval [CI], $400-$505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was $33,344 (95% CI, $31,553-$34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% CI, $43,254-$52,200; p = 0.061). Conclusion: In the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure.
UR - http://www.scopus.com/inward/record.url?scp=84925870771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925870771&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000283
DO - 10.1097/JTO.0000000000000283
M3 - Article
C2 - 25105438
AN - SCOPUS:84925870771
SN - 1556-0864
VL - 9
SP - 1449
EP - 1458
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -